Treatment for Blunt Cerebrovascular Injuries: Equivalence of Anticoagulation and Antiplatelet Agents  by Cothren, C.C. et al.
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 5 Abstracts 1243Summary: The effect of obesity in predisposing to hypertension,
cardiovascular diseases, and type 2 diabetes is serving to negate the gains in
life expectancy achieved over the past decades. A meta-analysis of 40 studies
involving 250,152 patients with coronary artery disease has demonstrated
that low BMI (20.0 kg/m2) is associated with higher total and cardiovas-
cular mortality than patients with normal BMI (range, 20.0-24.9 kg/m2).
In fact, total and cardiovascular mortality was lowest among those who are
overweight but not obese, defined as a BMI between 25.0 and 29.9 kg/m2
(Lancet 2006;368:666-78).
In this study, the authors explored the relationship between BMI and
cardiovascular events in patients enrolled in the Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, and Avoidance
(CHARISMA) study. CHARISMA was a multinational double-blinded,
placebo-controlled, randomized, clinical trial that evaluated the efficacy of
clopidogrel in patients with atherothrombotic disease or multiple risk factors
for atherothrombotic disease who were also receiving aspirin. This is a
subanalysis of the CHARISMA data stratified for BMI. Primary end points
included cardiovascular death, myocardial infarction, or stroke as well as
all-cause mortality and bleeding complications. Follow-up was for a median
of 28 months. Varying the patients with the highest BMI quartile to those
with the lowest BMI quartile, the primary end point, cardiovascular, and
all-cause mortality all were more frequent in those in the lowest BMI
quartile. The cutoff for all cause mortality and continuous BMI was 29.9
kg/m2.
Comment: The relationship between BMI and cardiovascular out-
comes is surprisingly complex. Mortality rates in the general population are
highest among those who are overweight and underweight. In the Physi-
cians’ Health Study of 5010 middle-aged men, relative risk for all-cause
mortality was 1.4 among those who had a BMI 22.0 kg/m2 compared
with those with BMIs between 22 and 24.9 kg/m2 (Arch Intern Med
2004;164:2326-32). It may be that the relationship between obesity and
mortality differs between individuals with and without cardiovascular dis-
ease. Certainly the data do not imply obesity is protective in patients with
cardiovascular disease, but it does appear that being underweight is detri-
mental to those with cardiovascular disease.
Treatment for Blunt Cerebrovascular Injuries: Equivalence of Antico-
agulation and Antiplatelet Agents
Cothren CC, Biffl WL, Moore EE, et al. Arch Surg 2009;144:685-90.Conclusion: Treatment of patients with blunt cerebrovascular injuries
with either antithrombotic therapy or antiplatelet therapy provides equiva-
lent results in terms of overall stroke risk.
Summary: Screening protocols for blunt carotid dissection based on
mechanism of injury and patient injury patterns are widely used for evalua-
tion of patients with possible blunt cerebrovascular injuries. When such
lesions are identified, treatment has traditionally been systemic hepariniza-
tion. In recent years, however, antiplatelet agents have been an increasingly
used alternative. The authors performed a retrospective review of their
prospective database of patients with blunt cerebrovascular injuries. Data
were collected from January 1, 1997, to January 1, 2007, at a level 1 trauma
center. The main outcome measure was the incidence of stroke, stratified by
treatment with anticoagulants or antiplatelet agents. During the study
period, 422 blunt cerebrovascular injuries were identified in 301 patients
(65% men) who were a mean age of 37 years. The mean injury severity score
was 27.0. Of 282 asymptomatic blunt cerebrovascular injuries, heparin was
used to treat 192, aspirin was used in 67, and aspirin and/or clopidogrel in
23. Only one treated patient had a CVA (0.5%). There were 107 patients
who had initially asymptomatic blunt cerebrovascular injures but were
untreated, and 23 (21.5%) had a CVA. For untreated patients, the mean
time from injury to CVA was 58  10 hours. Healing of injuries (heparin,
39%; aspirin, 43%; aspirin/clopidogrel, 46%) and injury progression (12%,
10%, 15%) were equivalent between therapies.
Comment: The data indicate some form of treatment, either antico-
agulation or antiplatelet therapy, should be used for patients with asymp-
tomatic blunt cerebrovascular injuries. Obviously, a 21% risk of CVA after an
initially asymptomatic blunt cerebrovascular injury is quite high. This risk
appears to be virtually eliminated by either antiplatelet or antithrombotic
therapy. Because the patients were not randomized, the choice of therapy
was either by surgeon preference or by surgeon assessment of the relative risk
of each therapy. The authors indicate in the discussion that a bias exists in
their institution to not use antiplatelet agents in patients when there is
evidence of intracranial bleeding. Little long-term follow-up was available,
so long-term effects of antiplatelet or antithrombotic agents on healing of
the blunt cerebrovascular injuries are unknown. Prompt initiation of anti-
thrombotic treatment should follow a diagnosis of blunt cerebrovascular
injury. Choice of therapy can still be individualized based on associated
injuries and perceived risk of bleeding.
